Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
We are committed to the legal development of regulated, safe & effective therapies, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.
Entheon Biomedical is a biotechnology company committed to the development of safe & effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders.
As evidenced by increasing rates of overdose deaths, societies all over the world have
found themselves ill-equipped and overburdened in managing and mitigating the
growing addiction crisis. More solutions are required to support and improve existing
recovery methods, in order to develop a treatment model rooted in innovation and
contemporary scientific findings.
Several of Entheon Biomedical’s founders have endured personal experiences with the
loss of loved ones due to the absence of suitable treatment options for issues ranging
from opiate addiction to treatment resistant depression. From this perspective, the
Company’s core mission is to investigate, manufacture, and commercialize scientifically
valid treatment options to address, ameliorate and treat the addiction crisis that is
plaguing many of our very own families and the modern world at large.
“Entheon Biomedical believes that people suffering from life-inhibiting addiction
disorders should have access to all scientifically-validated treatment protocols, and is
committed to the development and commercialization of psychedelics that are FDA,
EMA and Health Canada approved medicines designed to address the mounting public crisis of addiction and substance-related disorders.”
– Timothy Ko, Entheon Biomedical’s CEO.
Another differentiator is that British Columbia-based Entheon focuses on DMT, a hallucinogenic tryptamine drug and the main active ingredient in the plant medicine Ayahuasca.
“Psilocybin and DMT are both tryptamines and work on many of the same receptors in the human body, as they are molecularly very similar,” Ko explained. “Much of the visual and emotional components of the experiences are similar, and it is possible to create psilocybin-like experiences with the appropriate dosing of DMT.”
DMT is widely found in many plant and animal species, and even in the human brain. This makes it a safer drug, Ko said.
“The molecule is very well tolerated and metabolized in humans,” he said. “DMT is well-known to be short-acting and intense, but if properly harnessed and administered, the experience can be elongated and smoothed out to be less jarring, and result in a therapeutically useful experience.”
Entheon Biomedical is a psychedelic R&D company investing in research and an intensive drug discovery program with the aim to commercialize a portfolio of psychedelic therapies specifically designed for the treatment of addictive disorders. Psychedelics have a long history in the treatment of addictive disorders, and
we are all very excited to be working alongside a growing community of scientists and
medical professionals to dispel and overcome the many misconceptions with respect to
the clinical use of psychedelics.
Current scientific trials, combined with the wisdom of indigenous societies, and
psychedelic research of the past, all point to a growing wealth of evidence legitimizing
psychedelic substances as a medical and healing tool that has the potential to
revolutionize the mental health sciences.
Entheon Biomedical is developing therapeutic formulations of psychedelic molecules
that are designed to create different experiences in ways that will facilitate the healing
process needed to resolve the underlying issues of addiction.
Entheon Biomedical seeks to put aside a portion of funds it raises, and profits from its
future operations, toward the preservation of the Amazon and the wisdom keepers of
the region, so that they may continue their important traditions of medicine and
Chief Executive Officer
Timothy Ko has a broad background of leading private ventures in the service sector,
investor relations, retail and technology. Most recently, he served as Director of
Hyperbridge Technology, a company focused on the development of decentralized
technologies that facilitate crowdfunding. Mr. Ko’s passion for the psychedelic space and its potential for therapeutic use is shaped by firsthand knowledge of the shortcomings of the current mental health system and through his exposure to psychedelics, which he credits with saving his life. Following the loss of a loved one to a decades’ long fight with mental health and addictions, and through his personal experiences, Mr. Ko has committed himself to developing and providing further access to the lifesaving potential of psychedelic medicines.
Matthew Johnson is a Professor of Psychiatry and Behavioural Sciences at Johns Hopkins, and an expert on psychoactive drugs and addiction. He is one of the world’s most widely published scientists on the human effects of psychedelics. Prof. Johnson
earned his Ph.D. in experimental psychology at the University of Vermont in 2004, and
has published over 110 peer-reviewed articles. Working with psychedelics for 16 years,
he published psychedelic safety guidelines in 2008, helping to resurrect psychedelic
Prof. Johnson was the 2019 President of the Psychopharmacology and Substance
Abuse Division of the American Psychological Association, and is the current President of the International Society for Research on Psychedelics. He has received continuous funding as a principal investigator for over 12 years.
Prof. Johnson has reviewed for over 75 scientific journals, and reviewed grants for the
National Institutes of Health, National Science Foundation, the United States Military,
and multiple governments outside of the United States and has presented his research
in 13 nations. He has been interviewed widely by media including 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, NPR, and Fox Business News.
Prof. Johnson and his research were featured in Michael Pollan’s recent best-selling book, “How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence”.
Dr. Carhart-Harris heads the Psychedelic Research Group within the Centre for
Psychiatry at Imperial College, London, where he has designed a number of functional
brain imaging studies with psilocybin (psychedelic mushrooms), LSD, MDMA and
DMT, plus a clinical trial of psilocybin targeting treatment resistant
depression. He has over 50 published papers in peer-reviewed scientific journals; two
of which were ranked in the top 100 most impactful academic articles of 2016. Dr
Carhart-Harris obtained his PhD in Psychopharmacology from the University of Bristol,
and prior to that, an MA in Psychoanalysis at Brunel University. He has an honorary
position at the University of Oxford.
Dennis McKenna is an American ethnopharmacologist, research pharmacognosist,
lecturer and author. He is the brother of well-known psychedelics proponent Terence
McKenna and is a founding board member and the director of ethnopharmacology at
the Heffter Research Institute. As advisor to Entheon, he brings with him decades of
research and insight.
Candidate, Scientific Advisor
Christopher Timmermann is a psychologist educated at the Catholic University of Chile
with a Masters in Neuroscience and Neuropsychological Therapy from the University of
Bologna. He is a PhD Candidate at the Centre for Psychedelic Research / Psychedelic
Research Group, based at The Computational, Cognitive and Clinical Neuroimaging
Laboratory (C3NL). His research focuses on the effects of DMT in the human brain.
Completing her PhD at the department of Neuropsychology and Psychopharmacology, at the faculty of Psychology and Neuroscience at Maastricht University, The Netherlands, Malin investigated the short-term and long-term effects of ayahuasca and 5-MeO-DMT in naturalistic settings, while simultaneously initiating several other studies on the psychedelic substance mescaline and the breathing practice known as Holotropic Breathwork (HB). Malin is currently working as a Research Assistant at The Centre for Psychedelic Research, at Imperial College London, led by Dr. Robin Carhart-Harris. Here she is investigating the effects of 5-MeO-DMT on mental health related variables, brain activity and consciousness together with Christopher Timmermann, PhD candidate.
Besides being a researcher investigating psychedelics as a novel treatment option for mood-related disorders and trauma, Malin is also an editor for the ‘Journal of Psychedelics Studies’, a board member of the American podcast-show known as ‘Psychedelics Today’, and the co-founder of the Norwegian Association for Psychedelic Science (Norsk Forening for Psykedelisk Vitenskap [NFPV]) whose main aim is to educate the general public as well as researchers, and mental health practitioners in Norway about psychedelics.
Director of Operations
Dr. Andrew Hegle has been an adjunct professor of Pharmacology at the University of
British Columbia since 2015. He has a background in molecular biology and
biochemistry and has published research investigating the role of membrane receptor
proteins in physiology, behavior and disease. Andrew’s main professional focus has
been in the creation and management of laboratory operations. To that end, Andrew
has held executive and operational management positions at several biotechnology
companies, and was a cofounder of both Cannevert Therapeutics and Canalytic
Laboratories in Vancouver. Dr Hegle has a long-held interest in the therapeutic potential
of psychedelic medicine and is delighted to commit himself to furthering this field.
Chief Science Officer
Dr. Christopher Gondi is a Research Assistant Professor – Departments of Medicine, Surgery and Pathology at the University of Illinois, College of Medicine, Peoria. He is a professor of cancer biology and has extensive experience dealing with brain tumors and pancreatic cancer, for which the survival rates are very low.
Knowing firsthand the difficulty many face as they approach the end of their lives, Dr. Gondi seeks to explore the therapeutic benefits of psychedelics in helping patients
reconcile their views and prepare for whatever exists beyond life. He also sees the transformative potential of these drugs in positively affecting the lives of those suffering from substance use disorders.
Yaron Eshel has 15 years of experience in Life Sciences innovation. Having led efforts
in product development, regulatory compliance, and operations, Mr. Eshel has worked
within start-ups as well as having consulted for them.
Eshel has navigated the US, European, Israeli and Australian regulatory agencies
including the registration of manufacturing facilities in the US, Central America, Israel
and Australia to Good Manufacturing Practice levels. Mr. Eshel has led clinical trials in
the US, Europe and Israel as well as worked with CRO’s all over the world.
Advisor of Ethics
Kenneth W. Tupper served as an Adjunct Professor in the School of Population and
Public Health at the University of British Columbia, and has been active in the field of
psychedelic studies for more than fourteen years.
Having completed an M.A. thesis and Ph.D. dissertation that developed the concept of
“entheogenic education,” a theoretical frame for understanding the kinds of learning that
can be realized through the circumspect uses of psychedelics as cognitive tools. His
other research interests include the cross-cultural and historical uses of psychoactive
substances; public, professional and school-based drug education; and creating healthy
public policy to maximize benefits and minimize harms from currently illegal drugs.
Mr. Tupper is also currently a member of the Clinical & Scientific Advisory Board of the
Multidisciplinary Association for Psychedelic Studies – Canada (MAPS-Canada) and
the Advisory Board of the Wasiwaska Research Centre in Brazil.
Dr. Walker received his pharmacology training at the University of London which
included a period of drug discovery training at Pfizer Ltd., (UK). Dr. Walker’s main focus has been in the discovery of drugs, both naturally occurring and synthetic, and he has
developed an expertise in traversing the path to successful drug discovery. Michael’s
commitment to the pharmaceutical/pharmacology industry includes 43 years of
instruction at UBC and numerous contributions to universities around the world. Over
the past 25 years, Dr. Walker was the founder or co-founder of eight different drug
discovery companies, both public and private, including Cardiome Pharma (TSX:COM)
in Canada and Verona Pharma Ltd. in London.
In addition, Dr. Walker has researched and published in numerous journals, periodicals
and other publications, while presenting widely at conferences around the world.
Dana Nohynek is the director of regulatory affairs and quality assurance at the
Canadian Institutes of Health Research. She holds a BSc (Honors) from the University
of Waterloo (1998), a MSc from the University of Toronto (2000) and a RAC
certification (2006) granted by the Regulatory Affairs Professionals Society (RAPS).
She has over 10 years of industry experience that includes the development of
regulatory strategies throughout various phases of clinical investigation, extensive
interactions with regulatory authorities, preparation and submission of applications to
health agencies in Canada, the United States and Europe. In addition, Ms. Nohynek
has implemented quality systems, developed internal training programs and
participated in agency audits. She has worked for small to mid-size biotech and
medical device companies as well as with large pharma. She is an executive member
of RAPS’s Southern BC chapter.
Preclinical, Regulatory Consultant
Evelina Rubinchik has over 25 years of industry and academic experience in drug
development. She specializes in the creation of product development plans and liaises
with the relevant regulatory authorities to ensure the acceptability of the plans.
Throughout her career she has designed multiple pharmacokinetic studies, as well as
spearheading pharmacokinetic and pharmacodynamic analyses. Ms. Rubinchik started
her own successful consulting practice in 2009, focusing on nonclinical toxicology and
pharmacology. She has worked with biotechnology companies in Canada, America and
Asia. She holds a B.Sc & M.Sc in Biochemistry and a Ph.D in Pharmacology.
BioEnsemble was established in 2006 and brings to all projects over 30 years of
industry experience from leadership in small, medium and large pharmaceutical
companies. Bioensemble has extensive experience in general management, business
development, commercial strategy, product marketing, life-cycle management, clinical development, manufacturing and fundraising & financing. And has been involved in over
100 healthcare partnering discussions, valuations, due diligence and transactions and
has developed and launched more than 20 brand products.
If you have a moment, check out some of our recent media coverage: a feature article
in Benzinga feature and an interview of CEO, Timothy Ko, by the emerging psychedelic
Psyched: Oregon Legalizes Psilocybin, Washington DC Decriminalizes Psychedelics, Cybin And Entheon To Go Public
MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp., October 28, 2020
Research Efforts From Entheon Biomedical Suggest Psychedelics’ Potential In Treating Chronic Addictions, Benzinga, October 15, 2020
When Will Psychedelics be Legal in the United States? November 2020